Spectral Genomics Inc.
This article was originally published in Start Up
Spectral Genomics Inc., aims to become one of the first, if not the first, to bring a diagnostic microarray through to FDA approval. Spectral belives its BAC clone arrays offer major advantages in detecting large scale chromosomal amplifications, deletions and rearrangements characteristic of cancers and many congenital defects. The speed and universality of the arrays make them potentially practical for low-cost, high-speed, and targeted diagnostic purposes.
You may also be interested in...
Recent clinical developments in the medical device industry, including developments in Artificial Limbs, Tissue-Engineered Therapy for ACL Tears, using Genes to Identify Early Atherosclerosis, and Stem Cell News.
Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.
Affymetrix can succeed long term if gene expression proves to be a viable method for assaying disease. For now, that core question-the extent to which genotype correlates with phenotype-is as much a matter of philosophy as it is demonstrable fact. But making that determination will take time-and much data. Meanwhile, with its first-mover advantage in technology development and a strong IP portfolio, the company's GeneChip will likely as not be the technology used to answer that question. And in that sense, the GeneChip technology is enabling. Thus, at least for the time being, Affymetrix is well positioned to grow its life sciences markets. And through a recent major deal with Roche, it could become a major player in the nascent but arguably huge market for array-based clinical diagnostics.